Search Results - "Golenkov, Anatoly K"

A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older by Harousseau, Jean-Luc, Martinelli, Giovanni, Jedrzejczak, Wieslaw W., Brandwein, Joseph M., Bordessoule, Dominique, Masszi, Tamas, Ossenkoppele, Gert J., Alexeeva, Julia A., Beutel, Gernot, Maertens, Johan, Vidriales, Maria-Belen, Dombret, Hervé, Thomas, Xavier, Burnett, Alan K., Robak, Tadeusz, Khuageva, Nuriet K., Golenkov, Anatoly K., Tothova, Elena, Mollgard, Lars, Park, Youn C., Bessems, Annick, De Porre, Peter, Howes, Angela J.

“…This phase 3, multicenter, open-label study evaluated the efficacy and safety of tipifarnib compared with best supportive care (BSC), including hydroxyurea, as…”
Get full text

Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma by Moehler, Thomas M, Feneberg, Reinhard, Ho, Anthony Dick, Golenkov, Anatoly K, Ludwig, Heinz, Kropff, Martin, Khuageva, Nuriet K, Hajda, Jacek, von Broen, Ingo, Goldschmidt, Hartmut

“…Imexon [AOP99.0001 (4-imino-1,3-diazobicyclo[3. 1. 0]-hexan-2-one)] belongs to a novel class of promising anticancer agents that induce tumor apoptosis through…”
Get full text